This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics CAAO and PAO Jonathan Gillis reported open-market sales of 69,835 shares of Voting Common Stock. The transactions occurred on April 27–28, 2026, across five sales at weighted average prices such as $28.94 and $30.83 per share. All sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025, and he continues to hold a direct equity position reported in the filing.
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 45,422 shares of Voting Common Stock in open-market transactions. The sales occurred on April 27, 2026 at weighted average prices of $28.96, $29.63, and $30.50 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Kreitzer directly held 211,190 shares of MapLight Therapeutics common stock.
MapLight Therapeutics, Inc. reported that directors Robert Malenka, M.D., Ph.D. and Jim Trenkle, Ph.D. have decided not to stand for reelection at the company’s Annual Meeting of Stockholders scheduled for June 23, 2026. The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace them. The company stated that Dr. Malenka’s and Dr. Trenkle’s decisions were not due to any disagreement with MapLight on its operations, policies, or practices.
MapLight Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 23, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of April 27, 2026, when 42,610,079 shares of voting common stock were outstanding, may vote online, by telephone or by mail.
Stockholders will vote on two proposals: the election of three Class I directors (Martin Babler, Troy Cox and incumbent George Pavlov) to terms expiring at the 2029 annual meeting, and the ratification of RSM US LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends a vote “FOR” all director nominees and “FOR” auditor ratification.
The proxy describes MapLight’s classified board structure, committee composition, independence determinations and governance policies, including an insider trading policy, anti-hedging and anti-pledging rules, and a clawback policy. It also details executive and director compensation, including 2025 salaries, cash bonuses and equity awards, along with a severance and change-in-control plan covering senior executives.
MPLT submitted a Form 144 notice reporting an intended sale of 45,422 shares of Common Stock (Restricted Stock Units) associated with an issuer entry showing $1,351,758.72 and a NASDAQ reference. The filing also shows a prior sale by Anatol Kreitzer of 3,316 shares on 04/15/2026 for $88,238.76.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting proposed sales of Common stock. The filing lists 3,590 shares sold by Jonathan Gillis on 04/15/2026 for $95,529.90, and discloses restricted holdings of 48,481 shares (Restricted Stock Units, 07/05/2024) and 21,354 shares (restricted pre-IPO vesting, 08/19/2019).
MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported a routine share sale linked to tax withholding. On April 15, 2026, he sold 3,316 shares of Voting Common Stock at a weighted average price of $26.61 per share to cover statutory tax obligations from vesting restricted stock units, and now holds 256,612 shares directly.
MapLight Therapeutics officer Jonathan Gillis, CAAO and PAO, sold 3,590 shares of Voting Common Stock in an open-market transaction at a weighted average price of $26.61 per share. According to the footnotes, these shares were sold solely to cover statutory tax withholding obligations tied to the vesting of restricted stock units.
After the sale, Gillis directly owned 251,054 shares, which includes 121 shares acquired under the company’s stock purchase plan on March 31, 2026. The sale price range for the transaction was between $26.6045 and $26.6093 per share.
MapLight Therapeutics General Counsel Kristopher Hanson reported small open‑market sales of Voting Common Stock primarily to cover taxes on vesting stock awards. He sold a total of 1,827 shares across three transactions at prices around $26.80, $27.01, and $27.49 per share, as described with weighted average price ranges in the footnotes.
A footnote states the transactions represent shares sold to satisfy statutory tax withholding obligations tied to restricted stock unit vesting, indicating these are mechanistic rather than discretionary sales. After these transactions and prior plan purchases, Hanson directly holds 190,165 shares of MapLight Therapeutics common stock.